Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al
UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh